The Patient
A walk with friends should be a simple thing. For many people living with chronic stable angina, it isn’t. Before they say yes, they’re running through questions no one else in the group is thinking about. How far are we going? Will I need to stop? What if the...
The Science Behind ECP
The science behind ECP starts with timing. External Counterpulsation (ECP) uses precisely timed compression and release to influence blood flow at two distinct phases of the heartbeat—with two complementary goals: support blood flow to the heart and reduce the work the heart has to perform.1 During diastole — support...
Coatesville’s Pression Replaces 700-Pound Cardiac Machine With a Rolling Cart
A cardiac therapy that can require a 700-pound machine and a room of its own now fits on a cart that rolls into any room…. VISTA.TODAY Pression Coatesville...
How a former Lockheed Martin scientist built a portable heart care device
After years of development and FDA clearance, Philly-area startup Pression is moving into manufacturing and sales. There’s a therapy for certain heart patients that can require a 700-pound machine and a dedicated room. During treatment, balloon-like cuffs squeeze a patient’s calves, thighs and hips in rhythm with the heartbeat….....
Wave PRO™ Now Commercially Available as First Unit Enters the Field
Pression has begun the commercial introduction of Wave PRO™, with the first unit now in the field with our sales team. Following FDA clearance, this marks an important next step for Pression as we introduce Wave PRO™ to cardiologists and healthcare facilities and begin expanding awareness of a new...
From Cardiac Care to the Operating Room: Pression’s Platform Earns a New Patent Allowance
We are excited to share that Pression has received a Notice of Allowance from the USPTO for our patent application “System and Methods for Synchronizing External Compression of a Limb for Surgical Use” (App. No. 18/417,968). Our core technology — cardiac-synchronized external compression — was built to treat Chronic...
Pression Receives FDA 510(k) Clearance for Wave PRO™ External Counter-Pulsation System
Pression, Inc., a medical technology innovator specializing in non-invasive circulatory health, announced today that it has received 510(k) Clearance from the U.S. Food and Drug Administration (FDA) for its Wave PRO™ External Counter-Pulsation (ECP) System. This milestone clearance allows Pression to commercially market its patented, cardiac-gated compression technology for...
Cardiology’s New Pillar: Why ECP is No Longer an “Alternative” (2025 Year in Review)
The landscape of External Counterpulsation (ECP) underwent a significant transformation in 2025, evolving from a "last-resort" treatment for refractory angina into a front-line therapy for microvascular disease, cognitive health, and post-viral recovery....
Pression Submits 510(k) to FDA
Following the successful conclusion of our WaveCREST Clinical Study, we are very proud to announce the submission of our 510K to FDA. This tremendous milestone was made possible through the tireless effort of our fantastic team and our partners. We look forward to bringing a non-invasive, cost-effective solution to...